Bringing Research to LifeAnnual Report 2011-2012

The MonTreal neurological insTiTuTe of Mcgill universiTyCentre of exCellenCe in CommerCialization and researCh

editors: natasha laliberté, sandra McPherson, PhD

The Montreal neurological institute is proud to be a Killam institution, one of five canadian institutions supported by the Killam Trusts. in 1966, the izaak Walton Killam Memorial endowment fund and fund for advanced studies were established at the Mni through the bequest of Dorothy Johnston Killam. These funds support the academic and training mission of the Mni, and play a crucial role in advancing our work in neuroscience.

The production of this report was made possible by the support of the Montreal neurological institute centre of excellence in commercialization and research award from the government of canada.

We would like to thank the faculty and staff of the Mni for contributing their time in presenting their research reports and results. We would also like to acknowledge the work of photographer owen egan. D

esign and production: cg

co

M.c

oM

1 MESSAgE FroM THE ProvoST, McgIll UNIvErSITy

3 MESSAgE FroM THE INTErIM DIrECTor, MoNTrEAl NEUrologICAl INSTITUTE

4 THE NEUro

5 gloBAl STrATEgy For THE CENTrE oF ExCEllENCE IN CoMMErCIAlIzATIoN AND rESEArCH AwArD

6 MNI CECr CorPorATE PlAN 2011-2012

7 FoUrTH yEAr rESUlTS AND oUTCoMES

7 CoMPArATIvE rESUlTS AND oUTCoMES

9 FUNDED ProjECTS 2011-2012

15 PUBlIC oUTrEACH AND ENgAgEMENT ACTIvITIES

17 CoMMErCIAlIzATIoN AND BUSINESS DEvEloPMENT

•industrypartners

•patentapplications

•revenuesgeneratedfromcommercialactivitiesin2011-2012

•revenuesgeneratedfromcoreservicesin2011-2012

18 MNI CorPorATE PlAN 2012-2013

19 FINANCIAl STATEMENTS

21 CECr INITIATIvES

23 govErNANCE

•cecradvisoryBoard

•cecrprogramandinternalrevieWcommittee

•cecrcommercialiZationcommittee

24 CECr INvESTIgATorS, STUDENTS AND PoSTDoCTorAl FEllowS

contents

1

in recognizing the Montreal neurological institute of Mcgill university with a centre of excellence in commercialization and research award, the government of canada also required that i, as Provost of the university must present an annual report on activities, demonstrating how the terms and conditions of the award meet the funding agreement (article viii).

i am, once again, proud to report on the accomplishments of the Mni, its investigators, students, and staff, and to acknowledge the wonderful contribu-tions that they have made thanks to the significant financial contribution and framework for innovation that the cecr award has provided. This annual report details their progress.

Mcgill continues to be recognized as one of canada’s premier research-intensive universities. The Mni is an outstanding example of Mcgill’s commitment to advancing the frontiers of knowledge, educating the next generation of researchers, and making significant and lasting contributions to society.

neuroscience is a dominant research paradigm at Mcgill. in that context, the Mni is the cornerstone of those endeavors. The recognition of Mcgill as one of the world’s leading publicly funded universities is buttressed by the reputation and impact of scholars at the Mni. indeed, the Montreal neurological institute propels Mcgill thanks to its global standing by engaging in new and exciting curiosity-driven basic research at the bench. in addition, thanks to the strong working relationship of the Mni with the Montreal neurological hospital (Mnh), Mcgill is at the cutting edge in transforming patient care by providing an environment for the rapid translation of scientific discovery into life-saving techniques and therapies.

message from the provost Mcgill university

2

indeed, the combination of the Mni and the Mnh is often referred to as “The neuro”. This unique partnership between basic, curiosity-driven research and discoveries and a commitment to bring new ideas quickly to the practice of medicine is enhanced, enriched, and guaranteed because of the co-existence of the Montreal neurological institute of Mcgill university and the Montreal neurological hospital of the Mcgill university health centre.

The success of the Mni’s cecr projects are a testament to the shared vision and the determination of the talented scientists that work at The neuro, and we look forward to building on this success as we prepare for new leadership and new discoveries.

as Provost, the chief academic officer after the Principal and the chief budget officer of Mcgill university, i take great pride in the Mni as a centre of excellence. let me outline a few of the highlights contained in this year’s annual report. Mni scientists working on the cecr have:

• applied for 10 patents over the last four years

• published 63 papers during the course of the cecr

• submitted 7 new papers to peer reviewed journals in 2011-2012

• trained a new cohort of scientists

• formed new commercial and business partnerships

• leveraged the CECR award more than 1.7-fold in terms of grants, revenues and gifts-in-kind.

i believe that this progress in innovation reflects precisely the goals and objectives of the cecr program. The Mni cecr continues to allow the dedicated faculty and research teams at The neuro to make significant inroads in our under-standing and effective treatment of neurological disorders.

let me close by thanking the government of canada for showing such faith in the Montreal neurological institute of Mcgill University by the 2007 Award recognizing it as a centre of excellence in commer-cialization and research. i trust that this report will allow you to consider the recognition of the Mni to have been truly in the national interest of canada.

With best regards,

Prof. Anthony C. Masi Provost, Mcgill university

3

This report summarizes the activities supported during the fourth year of the cecr award to the Mni, a unique combination research institute and hospital. For more than 78 years, The neuro has brought together the finest minds in the field of neuroscience with a clinical culture that understands pressing unmet medical needs. our scientists, clinicians, nurses, staff and trainees work with intensity and passion to produce fundamental discoveries in the neuro-sciences and apply them to the treatment of neurological disease and injury. With the support of the cecr and by uniting our efforts, we are able to take on difficult problems and make the conceptual leaps that make a difference. The cecr award has supported some of canada’s brightest students and researchers, and provided access to sophisticated core platforms and innovative research and technologies at The neuro. The cecr award has enhanced our ability to move our initiatives forward and is yielding benefits for the people of canada.

Philip A. Barker, PhD interim Director Montreal neurological institute

message from the interim director Montreal neurological institute

4

A Global Challenge

Brain disorders affect 1 in 3 Canadians. according to health canada, the economic burden of neurological and psychiatric diseases, disorders and injuries is conservatively estimated at 14% of the total burden of disease, or $22.7 billion annually. As the population ages, these costs will increase dramatically. in the next 20 years, neurological conditions will become the leading cause of death and disability, magnifying the burden of neurological diseases on patients, their families, our health care system, and society.

it is imperative that new treatment options be identified and put into medical practice.

a unique institution

A teaching and research institute dedicated to innovations in neuroscience

From its inception in 1934, the Montreal neurological institute and hospital (The neuro) has been at the forefront of research into the causes and the treatment of neurological disease. it is one of the largest neuroscience institutes in the world, recognized for the seamless integration of neuroscience research and clinical neurology. clinicians at The neuro see the most difficult neurological and neurosurgical cases. We have 40 clinical trials for various diseases underway. our scientists have been a leading force in developing brain-imaging technologies, the first magnetic resonance imaging (Mri) and positron emission tomography (PeT) scanners in canada were at the neuro, and the scientific community uses The neuro stereotaxic space as a reference

for human and primate brain scans. neuro scientists are known worldwide for their pioneering research with approximately 1,000 high impact papers published in international, peer-reviewed scientific journals in the last five years alone. Thus, The neuro is a resource for all of canada.

The neuro’s goal is to provide an environment that allows neuroscientists and clinicians to identify the cellular basis of neurological disease and to translate these findings to innovations in clinical practice. We strongly believe that these innovations are best driven by the researchers and clinicians who are experts in their respective areas. The Mni’s status as a premier neuroscience institute and care facility attracts leading investigators, accomplished clinicians and promising students. We maintain key collaborations with neuroscientists not only across the mcGill network, but also with scientists in other universities and centres across Quebec and Canada, and around the world. The numerous awards received by our investigators and clinicians, our outstanding success rate in obtaining grants and the wealth of publications in leading scientific journals attest to our standing as a world-class institute with an extremely strong international reputation.

Applying research to understanding and treating neurological diseases

as a teaching and research institute of Mcgill university, the Mni is the centerpiece of Mcgill’s strategic plan in research and training in the neurosciences. More than 50 faculty members lead international research teams that generate research and translational support from grants, awards and contracts of approximately $22 million per year. our multidisciplinary teams generate fundamental information that

spans the full spectrum of neuroscience from cell and molecular biology to brain imaging and cognitive neuroscience. over 300 graduate students and postdoctoral fellows from around the world pursue their studies and scientific training at the Mni each year.

A centre for state-of-the-art treatment of neurological diseases

The Mni’s clinical partner, the Montreal neurological hospital, is one of five hospitals in the Mcgill university health Centre (MUHC). The hospital has 85 beds, five surgical suites, state-of-the-art equipment for interventional neuro-radiology, advanced cT, PeT, Meg and Mri scanners, ten specialty day clinics and other facilities. neurologists, neurosurgeons and other specialists hold academic appointments at Mcgill university and train the next generation of physicians.

the neuro

5

the mni’s strategy for use of the CeCr award focuses on two major endeavours: developing innovative approaches to research that will lead to effective applications to health care and creating opportunities for commercialization of diagnostic or treatment measures. the mni is pursuing its strategy through five general objectives.

objective 1

accelerate new research in the areas of:a) biological basis of neurological diseaseb) neuroengineeringc) translational neuroscienced) applied neuroscience

and commercialization

objective 2

enhance clinical trials programs to support work in translational neuroscience This objective focuses on the development of three programs: the experimental Therapeutics Program; an investigator-initiated clinical trials program; and web-based translational tools designed to bring research results and best practices to physicians and other health care providers. The Mni is also establishing an international network for the Mcconnell Brain imaging centre. These measures aim to facilitate access to academic and clinical resources, data and expertise for researchers and trainees.

Objective 3

engage domestic and international students and young researchers in our programs The Mni will increase opportunities for students, fellows and young researchers to be deployed to various research teams funded by the cecr award.

objective 4

facilitate intellectual property protection, commercialization of research results, and business development of mni inventions This objective will be achieved through the Mni’s initiative in applied neuroscience and commercialization. a panel of business, financial and scientific consultants who have extensive experience in biotech-nology and pharmaceutical industries will oversee commercialization activities.

objective 5

expand public outreach and engagement activities The Mni will allocate funding to support:

• an International Student and Fellowship Program;

• an annual MNI conference series designed to bring top tier international scientists to Montreal to present their latest work in areas of clinical importance and emerging research technologies;

• the development of web resources and new media for communicating our research and results to the lay public.

global strategy for the centre of excellence in commercialization and research award

6

ProjeCteD unsPent CoMMitteD funDs* for 2011-12 were DefineD As follows:

investigator initiated Programs

Biological basis of neurological disease, early stage commercialization $408,476

neuroengineering $122,232

Translational neuroscience $612,456

applied neuroscience and rapid commercialization $164,081

clinical trials support $ 50,370

Public outreach and engagement

fellowship Program $ 88,305

Mcgill integrated neuroscience Program $167,597

Media relations and outreach $157,851

intellectual property protection and business development $277,743

opportunity fund $467,316

administration $167,815

total $2,684,242

In Year 4, we maintained the objectives that were part of the long-term strategy originally defined in 2008-2009 and ensured the effective use of the CECR Award.

As per the funding agreement, the remaining funds of the $15M CECR grant were committed in Year 3.

For Year 4 we requested that all recipients with monies remaining in their respective project funds submit a description of their progress to-date, including reasons for project delays, if applicable; justification for extending their funding end-date beyond May 31, 2011; and a revised time line.

Mni cecr corporate plan 2011-2012

* As per Article V, section 5.1, of our Funding Agreement all funds were committed by March 31, 2010.

Our short term goals for 2011-2012 focused on reviewing Year 4 renewal requests, meeting with our CECR Advisory Board and confirming Year 4 funding. Our medium term goal was to facilitate the growth of the commercial ventures that had been initiated with the establishment of appropriate management and oversight and governance structures for these entities.

Please see pages 21-22 for the list of projects.

7

comparative results and outcomes

in the fourth year of the CeCr award:

• The Mni attained the objectives that it set out in its 2011-2012 Corporate Plan.

• The MNI received $350,000 in donations towards the purchase of equipment and $507,272 to support CECR funded projects.

• More than 30 published research papers resulted from research conducted on equipment at the Microscopy centre.

Mni principal investigators, as part of their CeCr-funded activities:

in the area of attracting top research talent:

• Engaged 21 Baccalaureate, Master’s and Doctoral students and 14 Postdoc-toral fellows from across north america and around the globe including Mexico, england, france, italy, iran, Korea, spain, india, chile, romania, Jordan, Belgium, Bahrain, algeria and china.

• Employed 28 research assistants, technicians and other qualified personnel.

in regard to commercialization of research and access to world-class resources:

• Generated revenues of $11,643 from commercial activities.

• Generated revenues of $2,734,122 from core services.

in pursuit of new collaborations with industry:

• Initiated industry collaborations and licensing agreements with five (5) companies in the pharmaceutical and biotechnology fields.

• Initiated one (1) new clinical collaboration.

in pursuit of internationally competitive research:

• Published 28 papers and submitted 7.

• Successfully applied for close to $1.1 million in funding from outside agencies.

in pursuit of the commercialization of leading-edge technologies:

• Filed two (2) new patent applications and moved an existing application to the international phase.

enhAnCeD ProDuCtivity AnD CoMPetitiveness

research-related benefits 2008-09 2009-10 2010-11 2011-12

Baccalaureate, Master’s and Doctoral students 15 52 39 21

Postdoctoral fellows 9 24 21 14

research assistants, technicians and other personnel 43 49 51 28

funding from outside agencies not applicable $5,000,000 $2,600,000 $1,100,000

Donations for purchase of equipment nil $1,300,000 $ 150,000 $ 350,000

Donations to support cecr funded projects nil nil nil $ 507,272

in-kind donations for neuroscience awareness nil $2,400,000 $ 900,000 nil

research papers published 2 16 17 28

research papers submitted nil 8 12 7

Commercialization-related benefits 2008-09 2009-10 2010-11 2011-12

new clinical collaborations not applicable 2 1 1

Pharmaceutical and biotechnology industry collaborations and licensing agreements 3 7 5 5new patent applications 4 3 1 2

revenue from commercial activities $ 60,000 $ 155,460 $ 130,192 $ 11,643

revenue from core services $2,893,210 $3,345,980 $3,212,345 $2,734,122

fourth year results and outcomes

9

10

funded projects

2011-2012

9

requests received in year 4 of the CECr Award were for end-date extensions as all funds had been committed in year 3 as per the Funding Agreement. requests were reviewed by core members of the CECr Program and Internal review Committee and all requests were approved.

35 applications were reviewed and funding extension recommendations for all were forwarded to our CECr Advisory Board for final approval.

In the pages that follow, we detail the work that the MNI CECr Award continued to fund in 2011-2012.

research reports

10

BIologICAl BASIS oF NEUrologICAl DISEASE new techniques in molecular and cell biology have greatly enhanced neurological disease research. it is now abundantly clear that most neurological disorders result from disruption in the fundamental function of brain cells and their interconnectivity. therefore, to understand normal nerve cell function and reveal how it is disrupted in models of disease, we must examine neurons at all levels; from the dynamics of sub-cellular organelles to the connectivity of cognitive networks.

Edward FonBiology of Parkinson’s Disease

The discovery of genes responsible for Parkinson’s Disease launched an intense amount of research. however, studies to identify the genes are rapidly outpacing the cell biological work needed to reveal how these genes are part of the disease process. This project examines known proteins implicated in Parkinson’s Disease to determine how they influence survival of neurons.

Michael PetridesAtlas of the Human Cerebral Cortex

The “Mni stereotaxic space” is a “generic” brain stereotaxic space created in 1994 and now used worldwide to specify the x, y and z coordinates of specific brain functions. But to identify the brain areas actually at those coordinates, investigators currently use assumptions modeled on a single brain. This Mni project is scanning normal human brains, analyzing them and incorporating the data into an updated 3D “MNI space”, resolving one of the most pressing problems in functional neuroimaging.

Philip BarkerJoint Protein Production Facility

new therapies for neurological disease are heavily dependent on recombinant proteins that are pure and free of endotoxins. generating these pure proteins in large quantities for in vivo testing is technically difficult and requires expensive infrastructure, so the Mni has partnered with the Biotechnology research institute (Bri) of the national research council (nrc). The cecr funding has provided for a joint Mni-Bri research assistant to supervise production of proteins at the Bri-nrc and to cover operating costs.

Thomas StrohMicroscopy Core Services

almost all fields of neurobiology require sophisticated microscopes and techniques to study the interactions of cells and cellular components of the brain. Since 2006, at least 100 high profile publications by Mni researchers contain data acquired in the institute’s Microscopy centre. cecr funding has been allocated to keep this centre at the cutting-edge, and the award funds specialized software and hardware, service contracts and technical management.

Eric ShoubridgeResource for the Generation of Induced Pleuripotent Stem Cells

The stem cell field was revolutionized by the finding that human skin cells, and probably many other cell types, could be induced to a pleuripotent (near-embryonic) state, from which they could be re-trained to become different cells altogether. While there is still much work to be done to fully characterize cells and perfect techniques, investigators can induce cells derived from patients with neurological diseases to become whatever cell type is required for modeling the mechanism of disease. stem cells have been generated at the Mni and the work is currently focused on differentiating them. The goal is to develop protocols permitting any investigator to “grow your own neurons.”

Barry BedellPlatform for Integrated, Advanced Animal Research for Complex, Human Neurological, Oncological and Inflammatory Diseases

This resource is an outgrowth of Dr. Bedell’s small animal imaging lab and creates an integrated technology platform that brings together multi-modality imaging, experimental neuropathology, and molecular studies. This novel platform integration will both increase and accelerate the commercialization opportunities for investigators by giving them a wider range of validation and investigative procedures. it will also help develop, over time, a pool of young talent specialized in these techniques which will make a sound contribution to the advancement of medical research in the community.

12

Alain DagherEffects of Stress on Eating Behaviour

obesity is a major health concern that has reached epidemic proportions in canada and in other countries. This study focuses on how the perception and experience of food and eating may impact brain chemistry and promote overeating. in particular, it seeks to determine if and how stress plays a part in causing overeating. a better understanding may lead to preventive strategies, both pharmacological and behavioural, to curb this epidemic.

Thomas StrohSuper-Resolution Imaging of Proteins

recent years have seen the discovery of genes responsible for many neurological disorders. now Mni researchers are working at the protein level to reveal how they interact to produce either a healthy life or the disease process. The most powerful optical microscopy is limited by the diffraction of light. cecr funding has permitted modifications of a microscope purchased with cfi funding and the associated image acquisition software, enabling its use for the acquisition of images permitting the localization of proteins of interest with approximately 50 nm (50 billionth of a meter) precision. This will revolutionize our understanding of how proteins within nerve cells cooperate to produce healthy function and which are the mechanisms leading to pathological malfunctions in the diseased brain.

NEUroENgINEErINgneuroengineering is a new revolution of science and technology using nano and biomedical engineering tools to answer neurobiological questions – understand, repair, replace, enhance, or otherwise exploit the properties of neural systems.

Eliane KobayashiApplication of MEG in the Assessment of the Epileptic Focus

surgery is the only treatment option for patients with drug-resistant focal epilepsy. however, localization of the seizure focus is not always possible, particularly in patients with normal brain imaging and eeg. Magnetoencephalography (Meg) is a neurophysiological tool that can provide important complementary information to the standard eeg investigation. Meg can identify the location and extent of the focus in a significant proportion of patients with negative eeg, particulary in cases of neocortical epilepsies. The neuro has recently installed a whole head Meg system. This is allowing us to study patients with focal epilepsies and to determine the role of Meg information in the surgical decision-making process.

Andrea BernasconiAutomated Lesion Detection in Drug Resistant Epilepsy

Dr. Bernasconi is developing an on-line commercial service to allow epilepsy centres throughout the world to deposit their Mri data into a central repository at the Mni. Data will be processed off-line on a secure server, and the processed results will be made commercially available to users through protected internet passwords and user-friendly software. The cross-platform software (Windows, linux and MacosX) will be updated regularly. The data repository will be an invaluable clinical tool. for example, three interdependent modules, will detect dysplasia features, and automatically detect and delineate tiny lesions that would otherwise remain unseen. collaborations are in the works with leading epilepsy centres (cnrs in Paris, Queen square, london, new york university, yale university, university of Melbourne) with other centres expected to join the repository in the coming years.

Robert ZatorreVisual Motion Sensitivity and Cochlear Implant Proficiency in Deaf Individuals

cochlear implants (ci) can restore hearing in the deaf by converting sound into electrical impulses delivered to the auditory nerve. however, ci efficiency varies greatly across individuals and it is known that sensory deprivation triggers cross-modal reorganization in the brain; that is the auditory cortex in deaf people can respond to visual inputs. little is known whether this plasticity may limit to some extent the ability to use ci. This cecr project will test the hypothesis that those who have greater degree of visual enhancement due to deafness may be at a disadvantage when learning to use cis. The results would have implications for predicting ci success, and potentially for helping to guide ci therapy.

TrANSlATIoNAl NEUroSCIENCEtranslational neuroscience applies insights gained through fundamental research on brain structure and function to develop novel pharmacological, surgical, and behavioral therapies for neurological diseases and disorders.

William FeindelCost-Effective Analysis of the Montreal Procedure for Surgical Cure of Temporal Lobe Epilepsy

opportunities to accurately measure the economic benefits of treatment are rare. The Mni has such an opportunity by having access to patients operated on between 1953 and 1988 by Dr. feindel, an associate of Wilder Penfield and a former neuro director. The surgical operation known as the “Montreal Procedure” developed by Penfield and his team in the 1950’s for temporary-lobe epilepsy is in use at over 100 neurosurgical centres around the world. This study is analyzing the benefits of having arrested the seizures by looking at the employment profile and earning capacity before and after surgery, as well as reduction in the costs of medication and government sponsored social welfare. Preliminary research has shown that lifetime economic benefits can be as high as one million dollars per operated patient.

Alain Dagher, Amir ShmuelEarly Diagnosis of Alzheimer’s and Parkinson’s Diseases

In Canada, Alzheimer’s Disease alone afflicts one in 20 people over 65 at an annual cost of treatment of $5.5 billion. international efforts to arrest the social and economic costs of dementia have led to the identification of drugs that may slow down the progression of this disease. This in turn drives renewed need for early diagnosis. The team is developing a suite of multi-modal tests – Mri, fMri, and diffusion-Mri – aimed at providing the biomarkers for early detection of alzheimer’s and Parkinson’s Diseases. The results are encouraging: in the model relating to alzheimer’s, the data differentiates patients with mild cognitive impairment, an intermediary stage, from control subjects; in the Parkinson’s model, the research differentiates subjects with dopamine depletion, related to Parkinson’s, from control subjects.

research reports

11

13

Kevin PetreccaTranslating DRR into a therapeutic target to prevent brain cancer invasion

a major problem facing brain cancer patients after surgery is the spread of remaining cancerous cells. Dr. Petrecca has discovered Drr, a protein which acts to spread cancerous glial cells. he and Dr. Masad Dahma of Mcgill university’s Department of chemistry have jointly patented two gene-based therapeutics that stop the action of Drr. one technique has been licensed to the american pharmaceutical firm, labopharm, while licensing for the second technique is under negotiation. although the therapies are not a cure, they promise to confine glioma brain cancer, a disease that kills two thousand canadians annually.

Bruce PikeMR Venography for Image Guided Neurosurgery

Pre-operative three-dimensional scans of the brain’s vasculature are an essential part of a surgeon’s preparation. But an easier, less expensive method is needed to replace the conventional Magnetic resonance imaging (Mri) technique based on injection of a contrast agent, which fails to differentiate arteries and veins, cannot detect the smallest vessels, and is time-consuming and costly. a new Mri technique called susceptibility weighted imaging (sWi) examines partially deoxygenated blood, allowing high-resolution images of tiny veins without the need of a contrast agent injection. We have combined this technique with Mri based imaging of arteries to produce dense 3D images of the brain’s blood vessels. These 3D vascular images are then utilized to automatically calculate optimal trajectories for procedures such as implantation of stimulating electrodes deep within the brain for the treatment of certain movement disorders such as Parkinson’s Disease. The end result of this research is expected to be a less expensive imaging procedure that produces superior quality vascular images that can be used to plan safer surgeries in less time.

Jean-Paul SoucyLaunching a SPECT imaging program at the Neuro

The neuro has acquired a sophisticated new brain-imaging tool for both clinical and research use. single-photon emission computer tomography (sPecT) uses a gamma camera that takes two-dimensional images from multiple angles in order to create a three-dimensional image. The device will mostly be used for epilepsy surgery planning, and the investigation of stroke and neurodegenerative diseases. The neuro’s sPecT machine was the fourth such machine to be produced. it significantly adds to The neuro’s world-class brain-imaging facilities.

Barry J. BedellArterial Spin Labeling Perfusion MRI in Clinical Studies of High-Grade Glioma

The creation of reliable biomarkers for use in the treatment of high-grade brain tumours is currently sought through dynamic contrast-enhanced magnetic resonance imaging (Dce Mri). however, the biological significance of the data generated by this technique is often difficult to interpret and there is a high (50%) failure rate due to technical challenges. arterial spin labeling (asl) Perfusion Mri offers distinct advantages over Dce Mri, but experience with asl Mri in brain tumours is limited. This project compared asl and Dce Mri technology via imaging studies of 10-15 patients with suspected, high-grade cerebral glioma. The data from this study will indicate whether asl can replace the existing method or whether it supplies different, complementary information and could be used in tandem.

research reports

Bruce PikeImaging Innovation and Translation

The Mni’s Mcconnell Brain imaging centre (Bic) is one of the world’s largest and most productive research-dedicated neuroimaging centres. Some 60+ faculty and another 200+ trainees utilize the BIC’s infrastructure and expertise in their clinical and basic neuroscience studies. This includes human MRI scanners at 1.5T and at 3T (for which there are over 100 active research protocols), a 7T small animal Mri, two human PeT scanners, a microPeT small animal system, a cyclotron and radiochemistry lab, a super-computing facility and a Meg scanner. not surprisingly, the Bic is also the most costly cog in the Mni mechanism. The centre runs on a cost-recovery model with an annual budget of approximately $4 million, aided by cecr funding of specific core costs. These funds have enabled at least 16 important accomplishments in the past year, including new patents and commercial contracts that have contributed significantly to the ongoing success of the Bic.

Amir ShmuelClinical Applications of Non-Invasive Manipulation of Neuronal Excitability

Transcranial Magnetic stimulation (TMs) offers an important, non-invasive means of manipulating neuronal activity to address neurological disorders and investigate the relationship between brain and behaviour. repeated application of TMs – rTMs – has been shown to alter cortical excitability beyond the period of stimulation. The promise of TMs, however, has been constrained by an incomplete understanding of how it works. a multi-faceted Mni team is documenting the biophysical principles of TMs and identifying exciting new potential therapies in the process. a pilot study of ambylopia, a common developmental visual disorder, indicates long-lasting improvements in vision can be achieved through application of rTMs to the visual cortex.

Denise KleinPre-Surgical Functional Brain Mapping Unit

At the MNI, approximately 200 patients a year undergo brain surgery in close proximity to areas critical to vision, movement, sensation or language. To improve pre-surgical mapping, Dr. Klein, a cognitive neuroscientist, has brought together experts from The neuro’s Brain imaging centre, neuroradiology and neurosurgery to create an integrated, pre-surgical functional brain mapping unit. With cecr funding, this unit has become well established and is scanning roughly two patients per week using new protocols developed by the team with functional magnetic resonance imaging (fMri) and positron emission tomography (PeT). a Director of neuro-navigation is working on the integration of the data with neuro-navigation systems for precise, image-guided neurosurgery.

Marilyn Jones-Gotman, Lesley Fellows, Alain PtitoThe MNI Cognitive Neuroscience Testing Resource

Tests of a patient’s cognitive abilities are important components of the diagnosis and treatment of epilepsy, head injury and other neurological disorders. By virtue of its work, the Mni has amassed a wide range of proven tests and, due to limitations in currently available commercial tests, the Mni batteries are much sought after. commercialization, however, requires a satisfactory set of normative data. This project will establish data on 300 healthy individuals stratified by age, sex and language as norms for use with patients with epilepsy or head injury, and on a cohort of patients with multiple sclerosis or hiv for use with patients with diffuse brain injury. it will result in the Mni marketing three batteries of specialized tests for different neurological conditions. To maximize user friendliness, most of the tests are being computerized and, to date, data have been collected from 145 patient test sessions and 180 sessions with healthy subjects.

11 12

14

David SinclairInnovative Vein Bypassing Technique in the Treatment of Cerebrovascular Disease

stroke is the leading cause of disability in north america. Bypass surgery is an important treatment to restore blood flow to the brain but conventional vein grafting has major drawbacks. one of the biggest is the need to shutdown the flow of blood during the operation, which risks more damage and requires the surgeon to work under pressure. elana is a laser assisted technique which does not interfere with cerebral blood flow and also permits bypass arteries with higher blood flows. This funding will help establish the Mni as the leading centre in vascular neurosurgery and establish the second elana capable system in canada.

APPlIED NEUroSCIENCE AND CoMMErCIAlIzATIoNtargeted research and development of resources for neuroscience and problems of the nervous system.

Peter McPhersonThe MNI Antibody Resource for Neuroscience Research

antibodies (abs) are a critical resource for neuroscience research, but custom abs are costly to generate and have a high failure rate. Dr. McPherson’s lab developed a novel hybrid approach for the production of epitopes used in custom antibody production, which simplifies and accelerates production. With cecr funding, a fully functional ab production facility has been established and is successfully producing and commercializing custom epitopes and antibodies for investigators at the Mni, Mcgill and outside Mcgill. In the 3 years since its inception, the Ab Centre of Excellence (AbCOE) has performed 115 projects for 13 investigators and 2 companies. The AbCOE has so far generated over $71,364 in fees and $45,513 in royalty payments.

Alyson FournierTargeting CRMP4b for Neuronal Repair

spinal cord injury is devastating in part because of the damage done to the central nervous system and because it is usually irreparable, consigning the patient to a lifetime of medical care. This is because the neurons and supporting cells are unable to spontaneously regenerate and restore functional communication in the central nervous system. Dr. fournier’s team identified the role of a protein, crMP4, in inhibiting neuron outgrowth and designed a competitive inhibitor termed c4riP to attenuate the outgrowth inhibition. But there are many forks in the research road: the first application of c4riP in an optic nerve injury paradigm has been unsuccessful and the team has now engineered a modification – TaT-c4riP – with which to continue the research.

Philip BarkerTargeting Neurite Growth Inhibitor Receptors to Promote Regeneration after Injury

The development of drugs that will enhance neuron repair after spinal cord injury remains one of the most sought-after research goals. This project brings together an impressive representation of the expertise available at the Mni with investigators experienced in biochemistry, signaling, cell-based models of neurite inhibition and preclinical models of spinal cord regeneration.

Gabriel LeonardComputerized Device to Measure Simple and Complex Hand and Arm Movements

Tapping tasks that involve out-of-phase coordinated movements of the two hands are reliable indicators of motor skill that is impaired after damage to regions of the frontal lobes. With cecr funding, Dr. leonard has successfully created a computerized tapping apparatus, which is portable, easy to use and can now record and report all error types. it is sought after by clinicians and researchers and has application for pharmaceutical research. Maximizing commercial sales of the apparatus requires extensive norms, linkage with normative data from the old apparatus, reliability measures and brain-imaging corroboration. These aspects of the project are well underway; eight computerized machines have been produced and three assistants hired. Well over 1,000 subjects (6 to 92 years of age) have been tested en route to a target sample of 2,000.

Amit Bar-OrIdentification of Novel Initiating Targets and Prognostic Markers of MS in Pediatric-Onset Disease

canadian children suffer one of the highest rates of Multiple sclerosis (Ms) in the world. Ms is the leading cause of neurological disability in young adults in the Western hemisphere and is caused by repeated attacks on the central nervous system by the body’s immune system. although treatments are able to partially reduce attacks, doctors are unable to tell at the time of the first attack whether this is isolated or whether it will progress into Ms. This project seeks to define the earliest molecular sites of the disease in order to identify biomarkers that can be used to predict the onset of Ms, and develop treatments best suited for early intervention in individual patients.

Amir ShmuelMonitoring Systems for MRI and Lab Environments

Dr. shmuel’s project specifically addresses common and costly issues in Mri- and lab-based research: recorded subject monitoring, the need to monitor any movement of the subject as to minimize blurs on the scan of alert subjects, and the need to assure an optimum anesthesia regime that will result in integrity of the data. To this end, Dr. shmuel, with the support of anesthesia-specialist Dr. gilles Plourde, developed two systems. The first system is a patient monitoring and data acquisition system for use in a regular lab and Mri scanner environment—there are currently four (4) fully functioning prototypes in use at The neuro. The second system is a system for monitoring and quantifying subject movements in real time in preparation training for Mri—there are currently two (2) functioning systems in use within Mcgill. interest is already growing in these systems and options on how to commercialize them are being explored.

Eric ShoubridgeMolecular Diagnostics Laboratory

a large number of neurological diseases are hereditary and identifying the genetic flaws allows for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. The Molecular Diagnostics laboratory offers unique genetic testing, adding to the Mni’s diagnostics capabilities as well as to its positioning as a leading-edge facility for neurological disease. To date, the lab has developed DNA-based tests for 18 different genes causing neuromuscular diseases; offers Dna based testing for all of the major disorders due to mutations in mitochondrial Dna; and is the only lab in north america to offer a biochemical test that provides a biochemical fingerprint of the respiratory chain defect. Due to changes made by the Quebec Government, effective April 1, 2011, billing for services between Quebec based hospitals is no longer permitted thereby limiting the ability to earn revenue. The lab is currently exploring various options including incorporating their services within an existing accredited clinical laboratory in the Mcgill system.

research reports

13

15

ClINICAl TrIAlS testing of medications and treatment devices for neurological disease in humans.

Amit Bar-OrExperimental Therapeutics Program

as a true expression of translational health research, the experimental Therapeutics Program (eTP) aims to bridge basic research in neurobiology and immunology with human studies of neurological and immune-mediated diseases. The program facilitates the translation of projects from the ‘bench’ to the ‘bedside’ through a range of activities with an overarching goal of expediting the development of emerging therapies for treating many neurological diseases. cecr funding has enabled the eTP to meet milestones in several areas such as the establishment of a state-of-the-art biorepository and generation of validated standard operating procedures (soPs), and has specifically supported the establishment of several platforms such as the luminex multiplex system and multi-color flow cytometry units that will also serve as core facilities to the Mni and external communities.

Angela Genge, Daria TrojanThe MNI Epidemiology and Biostatistics Unit for Clinical Research

epidemiology and biostatistics represent a link in the research chain that depended upon resources outside the Mni. This cecr funding served to establish a new internal unit which will expand clinical research and further the development of new treatments and methods. The epidemiologist hired in the first year of funding continued to work on a core program and the development of a user fee schedule that will help cultivate commercial potential.

research reports

Louis CollinsDevelopment of MRI tool to facilitate the development of drugs to treat prodromal Alzheimer’s Disease

alzheimer’s Disease has a signature mode of brain atrophy that differs from those of other dementias, but so far, the only sure way to confirm alzheimer’s Disease is by a post-mortem examination. Dr. collins and his colleagues have developed a non-invasive technique to predict both the early onset of the disease and the pace of its progression with a high degree of accuracy. The technique involves using Mri to measure changes in the shape of the living brain. By correlating the changes to a database of thousands of patients, Dr. collins can predict whether a patient will stay stable or get worse. eventual commercialization of the technique could lead to a significant reduction in the number of patients involved in clinical trials, resulting in huge savings for pharmaceutical companies.

Andrew ReaderScanner-Adaptive Image Reconstruction Platform for Accelerated Technology Transfer in Positron Emission Tomography

This project is creating an image reconstruction platform capable of handling data produced by different Positron emission Tomography (PeT) systems. This software permits the latest developments in image reconstruction technology to be applied to a wider range of PeT systems. The platform’s algorithms will allow image reconstruction, data correction and simulation for a range of PeT systems, all within a common framework. readily adaptable to any PeT system, the platform will facilitate further research developments in image reconstruction along with easier integration with other image-processing software. The platform aims to overcome the obstacles of adapting new reconstruction algorithms to a given scanner, opening up commercial potential.

Viviane SziklasA cost-effective fMRI solution to replace invasive examination of medial temporal lobe functions

Temporal lobe epilepsy surgery can potentially damage those regions involved in memory, so a pre-operative test called the intracarotid anesthetic Procedure is used to estimate a patient’s memory function. The test has several drawbacks: it is invasive, re quires several trained people over a three-day period, and uses a drug that is unavailable in some parts of the world. Dr. sziklas and Dr. Jones-gotman have developed a far more advantageous test using functional magnetic resonance imaging. The procedure is based on verbal and nonverbal memory tests that were honed over time so that their results are more precise in determining which region of the brain is of interest to the surgeon. The two researchers also developed a second similar test for use as a follow up to the first. The procedure’s commercial application extends worldwide, particularly to epilepsy centres in europe, where trained staff and specific drugs are often lacking.

13 14

15

funds from the cecr award have been allocated for educational and outreach activities. The investment of cecr funds has leveraged additional funds from the private sector and will lead to long-term educational benefits, including transferring knowledge and inspiring the next generation of scientists.

institute and international fellows Program The cecr fellowship is a two-year fellowship that supports research and study in clinical and basic neuroscience. a total of 15 fellowships were awarded between 2008 and 2010. In 2010-11, we supported eight (8) post-doctoral fellows with awards of $40,000 per year. several former cecr post-doctoral fellows have gone on to accept research and academic positions in countries around the world including china, france, and switzerland.

Mcgill integrated Program in neuroscience and student rotation Program The Mcgill integrated Program in neuroscience (iPn) is an initiative and expansion of the graduate Program in neuroscience. The iPn is in line with Mcgill university’s emphasis on neuroscience and its strategic Plan to attract top graduate students. it is the largest graduate program in the faculty of Medicine and one of the largest neuroscience graduate programs in north america.

Mcgill has a high concentration of neuroscientists, but they are spread throughout different departments, hospitals and research institutes across Montreal. The iPn is a multi-disciplinary, inter-departmental program that brings together all graduate training in neuro-science currently under the Mcgill umbrella, and offers prospective students a single consolidated program through which to apply for and attain their Msc or PhD in neuroscience. The program currently comprises 160 faculty and almost 300 graduate students. All aspects of the student experience, including the program’s website; applica-tion and supervisor selection procedures; tracking the attainment of milestones; and student awards, were evaluated and improved when the iPn was introduced.

an exciting festure of the iPn is a rotation Program which benefits outstanding students who wish to try their skills in several different laboratories for their first year, before committing to a supervisor for the rest of their graduate work. The first six (6) students in our rotation Program completed their rotation in September 2011 and five (5) additional students are set to complete their rotation in September 2012.

integrated Program in neuroscience retreat (September 20-21, 2011)The integrated Program in neuroscience (iPn) retreat continues to provide an unprecedented opportunity for Mcgill researchers from all disciplines of neuroscience to come together and share their work interests with one another. attendance at the two-day event was mandatory for all new students admitted to the iPn, and personnel from iPn labs were also invited. 450 people pre-regis-tered for the retreat. With poster ses-sions (86 posters), overview talks and themed sessions, Mcgill’s contributions to the world of neuroscience research were showcased at the retreat. sched-uled activities encouraged interaction among students, postdoctoral fellows and principal investigators and represented the full depth and breadth of Mcgill neuroscience. The next annual iPn retreat will be held September 19-20, 2012.

public outreach and engagement activities

17

17

industry partners The Mni has a long history of partnerships with industry and lists a number of major companies in its collaborations. among them are the following:

• Archemix Therapeutics• AstraZeneca• Aventis• Biogen Idec• GE Medical Systems• Genentech• Lantheus Medical Imaging • MediMabs• Medtronic• Millennium Pharmaceuticals• Millipore• Neuromics• PainCeptor Pharma• Proportional Technologies Inc.• Takeda Pharmaceuticals Inc.• Teva Neuroscience

as well, Mni investigators founded several companies over the last few years as part of their technology and knowledge transfer initiatives:

• Aegera Therapeutics• Biospective• PainCeptor Pharma• Stellate

The projects funded through the cecr award have enabled further collaborations with industry. In 2011-2012 collaborations have been confirmed with labopharm, caprion Proteomics, novartis, Medtronic, and The centre for Drug research and Development.

Patent applications Results of seven (7) CECR-funded projects since 2008 are the object of patent applications:

alyson fournier

Targeting crMP4b for neuronal repair– national phase in canada, the united

states, europe and Japan

Philip Barker

Targeting neurite growth inhibitor receptors to promote regeneration after injury– lgi1: national phase in the united states

tim Kennedy

generation and characterization of novel compounds to inhibit cell migration– netrin: Provisional patent application

filed in the united states– Patent cooperation Treaty (PcT) patent

application filed (2009-2010)

david Colman*/amit Bar-or

Pediatric Ms biomarkers– cadherin: Proof of concept stage– national phase in canada, the united

States and Europe (2009-2010)– Patent application filed

* Deceased June 1, 2011

Gabriel leonard

a new computerized device to measure simple and complex hand and arm movements– Provisional patent application filed

in the United States (2009-2010)– Patent cooperation Treaty (PcT)

international patent application filed (2010-2011)

ralf schirrmacher

imaging innovation and translation (Bruce Pike)– Thiol-Nota Derivatives for Kit68Ga

radiolabeling: Patent cooperation Treaty (PcT) patent application filed (2009-2010)

– ligands for Targeting Pancreatic alpha and Beta cells: Patent cooperation Treaty (PcT) patent application filed (2009-2010)

Kevin Petrecca

Translating Drr into a therapeutic target to prevent brain cancer invasion– Provisional patent application filed

(2010-2011)Method for treating brain cancer (antisense) (2011-2012)– Provisional patent application filedMethod for treating brain cancer (sirna) (2011-2012)– Provisional patent application filed

revenues generated from commercial activities in 2011-2012Peter mcPherson

The Mni antibody resource for neuroscience research $11,129

eric shoubridge

Molecular Diagnostics laboratory for neurological Diseases $514**

revenues generated from core services in 2011-2012amit Bar-or

experimental Therapeutics Program$353,252

Bruce Pike

Mcconnell Brain imaging centre$2,343,785

thomas stroh

Microscopy core services$37,085

** Due to changes in provincial regulations for billing, the ability to earn revenue was limited.

commercialization and business development

18

in year 5, we will continue to maintain the objectives that were part of the long-term strategy originally defined in 2008-2009 and to ensure the effective use of the CECR Award.

as per the funding agreement, the remaining funds of the $15M cecr grant were committed in Year 3. For Year 5 we implemented the same process as in Year 4 with exception that May 31, 2013 will be identified as the final end date for expending any remaining funds.

Projected unspent committed funds* for 2012-13 are defined as follows:

Mni corporate plan 2012-2013

investiGator initiated ProGrams

Biological basis of neurological disease, early stage commercialization $ 76 283

neuroengineering 0

Translational neuroscience 45 447

applied neuroscience and rapid commercialization 58 012

clinical trials support 0

PuBliC outreaCh and enGaGement

fellowship Program 6 973

Mcgill integrated neuroscience Program 34 864

Media relations and outreach 136 302

intellectual property protection and business development 214 013

opportunity fund 244 784

administration 84 962

totAl $901 640* As per Article V, section 5.1, of our Funding Agreement all funds were committed by March 31, 2010.

Our short term goals for 2012-2013 focus on reviewing Year 5 renewal requests, meeting with our cecr advisory Board and confirming year 5 funding. our medium term goal is to facilitate the growth of the commercial ventures that have been initiated, with the establishment of appropriate management and oversight and governance structures for these entities.

19

financial statements

indePendent auditor’s rePort

To the management of the

royal institution for the advancement of learning (Mcgill university)

We have audited the accompanying statement of revenue and expenses and funds available of Mcgill university (the “university”), of which the Montreal neurological institute of McGill University (the “Institute”) is a department for the period from June 1, 2011 to May 31, 2012, and a summary of significant accounting policies and other explanatory information (together “the statement”). The statement has been prepared by management of the university based on the accounting policy described in the accompanying note.

management’s responsibility for the statementManagement of the university is responsible for the preparation of the statement in accordance with the basis of accounting described in the accompanying note; this includes determining that the applicable financial reporting framework is acceptable for the preparation of the statement in the circumstances, and for such internal control as management determines is necessary to enable the preparation of the statement that is free from material misstatement, whether due to fraud or error.

auditor’s responsibilityour responsibility is to express an opinion on the statement based on our audit. We conducted our audit in accordance with canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement.

an audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the statement. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. in making those risk assessments, the auditor considers internal con-trol relevant to the entity’s preparation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. an audit also includes evaluating the ap-propriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

opinionin our opinion, the statement of revenue and expenses and funds available of the institute for the period from June 1, 2011 to May 31, 2012 is prepared, in all material respects, in accordance with the basis of accounting described in the accompanying note.

Basis of accounting and restriction on useWithout modifying our opinion, we draw attention to the accompanying note related to the statement, which describes the basis of accounting. The statement is prepared to assist the University to meet the requirements of paragraph 8.2 of the agreement signed in 2008, between McGill University and the Minister of Industry. As a result, the Statement may not be suitable for another purpose. our report is intended solely for the Minister of industry and the university and should not be used by parties other than the Minister of industry and the university.

November 6, 2012

1 CPA auditor, CA, public accountancy permit No. A125888

samson Bélair/deloitte & touche s.e.n.c.r.l.

1 Place ville Marie Suite 3000 Montréal QC H3B 4T9 canada

Tel: 514 393-7115 Fax: 514 390-4116deloitte.ca

1

20

statement of revenueand expensesand funds available

mcGill universitYfundinG aGreement With the minister of industrY

statement of revenue and expenses and funds availablefor the period from June 1, 2011 to May 31, 2012

funds available, beginning of year $3,393,580

revenue

interest 63,822

expenses

salaries 961,192

fringe benefits 93,054

Material and supplies 440,413

contract and consultant services 52,904

Travel 23,418

equipment 34,793Miscellaneous 444,288

2,050,062

excess of expenses over revenue 1,986,240

funds available, ending of year $1,407,340

accounting policy

Management is responsible to determine the basis of accounting since it is not defined in the agreement signed in 2008 between McGill University and the Minister of Industry. Management selected the recognition and measurement criteria of generally accepted accounting principles of Part v of the canadian institute of chartered accountants (cica) handbook.

21

As per the funding agreement, the remaining funds of the $15M CECR grant were committed in Year 3. The following projects and initiatives submitted requests for end-date extensions and were active in 2011-2012.

cecr initiatives

investiGator BioloGiCal Basis of neuroloGiCal disease finanCement

Michael Petrides Atlas of the Human Cerebral Cortex 100 000 $

Barry j. Bedell PIA -ArACHNoID—Platform for Integrated, Advanced Animal research for Complex Human Neurological, oncological and Inflammatory Diseases

150 000 $

Edward Fon The Cell Biology of Parkinson’s Disease 75 000 $

Philip Barker The joint MNI – BrI Protein Production Facility 75 000 $

Thomas Stroh Microscopy Core Services 130 000 $

Eric Shoubridge resource for the generation of Induced Pleuripotent Stem Cells 70 000 $

Thomas Stroh Multi-colour Superesolution Imaging in Fluorescently Tagged Proteins

Alain Dagher The Effects of Stress on Eating Behaviour and Brain Activity: a Functional Magnetic resonance Imaging (fMrI) Study

investiGator neuroenGineerinG finanCement

Eliane Kobayashi Application of Magnetoencephalography in the Assessment of the Epileptic Focus 90 000 $

Andrea Bernasconi Automated lesion Detection in Pharmacoresistant Epilepsy 80 000 $

robert zatorre Deaf-Blindness: Cross-Modal reorganization and Cochlear Implant Proficiency

investiGator aPPlied neurosCienCe and CommerCialization finanCement

Peter McPherson The MNI Antibody resource for Neuroscience research 50 000 $

Eric Shoubridge Molecular Diagnostics laboratory for Neurological Diseases 150 000 $

Alyson Fournier Targeting CrMP4b for Neuronal repair 68 100 $

Philip Barker Targeting Neurite growth Inhibitor receptors to Promote regeneration After Injury 100 000 $

gabriel leonard A New Computerized Device to Measure Simple and Complex Hand and Arm Movements 75 000 $

Amir Shmuel Monitoring Systems for MrI and lab Environments 130 500 $

Amit Bar-or Identification of Novel Initiating Targets and Prognostic Markers of MS in Pediatric-onset Disease

119 267 $

louis Collins Development of MrI Tools to Facilitate the Development of Drugs to Treat Prodromal Alzheimer’s Disease

128 000 $

Andrew reader Scanner-Adaptive Image reconstruction Platform for Accelerated Technology Transfer in Positron Emission Tomography

150 000 $

viviane Sziklas A Cost-Effective fMrI Solution to replace Invasive Examination of Medial Temporal lobe Functions

85 050 $

22

investiGator translational neurosCienCe finanCement

william Feindel Cost-Effective Analysis of the Montreal Procedure for Surgical Cure of Temporal lobe Seizures

40 000 $

Alain Dagher Amir Shmuel

Early Diagnosis of Alzheimer’s and Parkinson’s Diseases 125 000 $

Bruce Pike Imaging Innovation and Translation 500 000 $

Marilyn jones-gotman lesley Fellows Alain Ptito

The MNI Cognitive Neuroscience Testing resource 100 000 $

Kevin Petrecca Translating Drr into a Therapeutic Target to Prevent Brain Cancer Invasion 110 000 $

Bruce Pike Mr venography for Image guided Neurosurgery 0** $

David Sinclair Excimer laser-Assisted, Non-occlusive Anastomosis (ElANA): An Innovative revascularization Technique in the Treatment of occlusive Cerebrovascular Disease

80 000 $

jean-Paul Soucy launching a SPECT Imaging Program at The Neuro 57 500 $

André olivier International Centre of Excellence in Neuro-Navigation

Barry Bedell Arterial Spin labeling Perfusion MrI in Clinical Studies of High-grade glioma

investiGator CliniCal trials finanCement

Amit Bar-or Experimental Therapeutics Program 250 000 $

angela genge / Daria Trojan

The MNI Epidemiology, and Biostatistics Unit for Clinical research

manaGer outreaCh and enGaGement finanCement

Thomas gevas Institute and International Fellows Program 140 000 $

Thomas gevas Mcgill Integrated Program in Neuroscience 60 000 $

Sandra McPherson Media relations, Public outreach and Education 255 000 $

manaGer neW oPPortunities finanCement

Thomas gevas opportunity Fund 235 000 $

manaGer intelleCtual ProPertY and Business develoPment finanCement

Thomas gevas Intellectual Property Protection and Business Development 300 000 $

manaGer administration finanCement

Thomas gevas Administration Costs 100 000 $

23

cecr advisory Board Mandate

To provide global oversight to ensure that the Mni centre of excellence in commercialization and research award meets the goals and terms of the agreement and that funding initiatives align with Mni strategic goals.

MembershipJacques Bougie, o.C.chair, cecr advisory Boardchair, The neuro advisory Boardformer President and chief executive officer,alcan aluminium inc.

max fehlmann, Phd, mBaPresident and ceo,Québec consortium for Drug Discovery (cQDM)

Gregory orleski, Ba, ll.B., BClBusiness Development advisor to the ceo,PharmascienceBoard member, The Maisonneuve- rosemont hospital foundationBoard member, Pediapharm inc.

cecr Program and internal review committee Mandate

• To ensure that the MNI’s Centre of excellence in commercialization and research funding decisions are consistent with goals outlined in the federal science and Technology strategy.

• To ensure that funding is allocated to high priority projects and distributed in a responsible manner.

• To evaluate proposals using criteria outlined in the competitive phase of the Mni centre of excellence in commercialization and research Program.

Membershipmartine alfonsoadministrative Director, neuroscience Mission, Mcgill university health centreinterim Director, Montreal neurologicalhospital

amit Bar-or, mdDirector, experimental Therapeutics Program and coordinator, clinical research unit, Mni

Philip Barker, Phdchair, cecr Program and internal review committeeinterim Director, Montreal neurological institute

robert dunn, Phdassociate Director, scientific affairs, Mni

thomas Gevaschief financial officer, Mni

elizabeth Kofron, Phdassociate Director, corporate affairs and special Projects, Mni

Peter mcPherson, Phdcoordinator, cell Biology of excitable Tissue, neurobiology unit, Mni

Bruce Pike, PhdDirector, Mcconnell Brain imaging centre, Mni

eric shoubridge, PhdDirector, Molecular neurogenetics, Mni

david sinclair, mdneurosurgeon, Mnh

cecr commercialization committee Mandate

• To review and advise on all potential commercial activities and charged with identifying the most promising technologies, providing input into intellectual property protection and developing commercialization strategies.

• To ensure that projects with commercial potential/aspects are provided the necessary tools/aids to avert failure.

MembershipPhilip Barker, Phdchair, cecr Program and internal review committeeinterim Director, Montreal neurological institute

thomas Gevaschief financial officer, Mni

timothé huot, ll.l.lawyer, Bcf

donald olds, msc, mBachief financial officer & chief operations officer,aegera Therapeutics inc.

emma saffman, PhdPatent agent, norton rose or llP

Patrick tremblay, Phdexecutive-in-residence, Pappas ventures

governanceThe cecr advisory Board, the Program and internal review committee, and the commercialization committee ensure, through their respective mandates, that management of the Mni cecr award is efficient, fair and transparent, and that funding is used towards stated objectives.

24

investigatorsBioloGiCal Basis of neuroloGiCal diseasePhilip BarkerBarry J. Bedellalain Dagheredward fonMichael Petrideseric shoubridgeThomas stroh

translational neurosCienCeBarry Bedellalain DagherWilliam feindellesley fellowsMarilyn Jones-gotmanDenise Kleinandre olivierKevin PetreccaBruce Pikealain Ptitoamir shmuelJean-Paul soucy

neuroenGineerinGandrea Bernasconieliane KobayashiRobert Zatorre

CliniCal trialsamit Bar-orangela gengeDaria Trojan

aPPlied neurosCienCe and CommerCializationamit Bar-orPhilip Barkerlouis collinsalyson fourniergabriel leonardPeter McPhersonandrew readeramir shmueleric shoubridgeviviane sziklas

studentsJenny Bellerosesilvain BeriaultJenea M BinMegan callahanDuncan cowieglen Deleaveyalix DudleyXu feihalleh ghaderiharald gjerdeolivia ishibashihosung Kimetienne létourneauhoratio olteanlisa PalladiniMai salehMartha shiellJoni shushatgina Trinhneil vermanyanqing Xu

PostdoCtoral felloWs anshul awasthihamed azarnoushsarah BanksDong hanamad KanaanMark KeezerMohammad KhazaeiKanchan Kumarieroberta laPianavictoria MeryManuel Porras-Betancourtisabelle suarezJeroen verhaegheMathieu vincent

cecr investigators, students and postdoctoral fellows

To obtain additional copies of this report or for more information, please contact:

External Affairs Montreal Neurological Institute and Hospital 3801 University Street Montreal, Quebec H3A 2B4

Tel.: 514 398-1902 Fax: 514 398-8072

Communications.mni@mcgill.ca www.mni.mcgill.ca

Le rapport est disponible en français.